Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Provided By GlobeNewswire

Last update: May 12, 2025

Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatment with efruxifermin (EFX)